FR2682039A1 - Compositions medicamenteuses destinees a favoriser le renouvellement a la matrice extracellulaire. - Google Patents
Compositions medicamenteuses destinees a favoriser le renouvellement a la matrice extracellulaire. Download PDFInfo
- Publication number
- FR2682039A1 FR2682039A1 FR9112599A FR9112599A FR2682039A1 FR 2682039 A1 FR2682039 A1 FR 2682039A1 FR 9112599 A FR9112599 A FR 9112599A FR 9112599 A FR9112599 A FR 9112599A FR 2682039 A1 FR2682039 A1 FR 2682039A1
- Authority
- FR
- France
- Prior art keywords
- synthesis
- collagen
- vectors
- vector
- drug compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 title claims description 15
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 title claims description 15
- 210000002744 extracellular matrix Anatomy 0.000 title claims description 15
- 230000008929 regeneration Effects 0.000 title 1
- 238000011069 regeneration method Methods 0.000 title 1
- 239000013598 vector Substances 0.000 claims abstract description 74
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 52
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 52
- 102000008186 Collagen Human genes 0.000 claims abstract description 46
- 108010035532 Collagen Proteins 0.000 claims abstract description 46
- 229920001436 collagen Polymers 0.000 claims abstract description 46
- 210000002950 fibroblast Anatomy 0.000 claims abstract description 34
- 210000004027 cell Anatomy 0.000 claims abstract description 22
- 230000000694 effects Effects 0.000 claims abstract description 15
- 102000012422 Collagen Type I Human genes 0.000 claims abstract description 10
- 108010022452 Collagen Type I Proteins 0.000 claims abstract description 10
- 102000029816 Collagenase Human genes 0.000 claims abstract description 10
- 108060005980 Collagenase Proteins 0.000 claims abstract description 10
- 239000003446 ligand Substances 0.000 claims abstract description 9
- 230000002503 metabolic effect Effects 0.000 claims abstract description 9
- 239000013543 active substance Substances 0.000 claims abstract description 4
- 239000003999 initiator Substances 0.000 claims abstract description 4
- 239000012528 membrane Substances 0.000 claims abstract description 4
- 230000010933 acylation Effects 0.000 claims abstract description 3
- 238000005917 acylation reaction Methods 0.000 claims abstract description 3
- 239000012736 aqueous medium Substances 0.000 claims abstract description 3
- 239000002775 capsule Substances 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 13
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 9
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 4
- 229960002591 hydroxyproline Drugs 0.000 claims description 4
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 4
- 208000002260 Keloid Diseases 0.000 claims description 3
- 150000002194 fatty esters Chemical class 0.000 claims description 3
- 210000001117 keloid Anatomy 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 abstract 2
- 239000000969 carrier Substances 0.000 abstract 1
- 125000000524 functional group Chemical group 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 23
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 11
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 11
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 11
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 9
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 9
- 238000011282 treatment Methods 0.000 description 8
- MLTOQTGCMBIFFL-MOPGFXCFSA-N (2s,4r)-4-hexadecanoyloxypyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@H]1CN[C@H](C(O)=O)C1 MLTOQTGCMBIFFL-MOPGFXCFSA-N 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 229960002424 collagenase Drugs 0.000 description 6
- 102000001187 Collagen Type III Human genes 0.000 description 5
- 108010069502 Collagen Type III Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000003328 fibroblastic effect Effects 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000003367 anti-collagen effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000036348 connective tissue physiology Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- -1 fatty acid ester Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical group CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 231100001231 less toxic Toxicity 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 108091007187 Reductases Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000003366 colagenolytic effect Effects 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002193 fatty amides Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9112599A FR2682039A1 (fr) | 1991-10-08 | 1991-10-08 | Compositions medicamenteuses destinees a favoriser le renouvellement a la matrice extracellulaire. |
| EP92420355A EP0537092A1 (fr) | 1991-10-08 | 1992-10-08 | Vecteurs vésiculaires infracellulaires et leurs applications dans les compositions cosmétiques, médicamenteuses et les milieux de culture |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9112599A FR2682039A1 (fr) | 1991-10-08 | 1991-10-08 | Compositions medicamenteuses destinees a favoriser le renouvellement a la matrice extracellulaire. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2682039A1 true FR2682039A1 (fr) | 1993-04-09 |
| FR2682039B1 FR2682039B1 (enrdf_load_stackoverflow) | 1995-03-03 |
Family
ID=9417858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9112599A Granted FR2682039A1 (fr) | 1991-10-08 | 1991-10-08 | Compositions medicamenteuses destinees a favoriser le renouvellement a la matrice extracellulaire. |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2682039A1 (enrdf_load_stackoverflow) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2852249A1 (fr) * | 2003-03-10 | 2004-09-17 | Christian Chavrier | Biomateriau de comblement osseux |
| JP2007182419A (ja) * | 2005-12-07 | 2007-07-19 | Tokyo Univ Of Science | プロリン誘導体及び光学活性アンチ選択性増強触媒 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2540381A1 (fr) * | 1983-02-08 | 1984-08-10 | Dior Sa Parfums Christian | Procede pour stimuler la croissance des cellules; composition cosmetique, pharmaceutique et composition complementaire pour milieu de culture cellulaire appliquant ce procede |
| EP0160286A2 (en) * | 1984-04-28 | 1985-11-06 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Liposomes |
| WO1987006460A1 (fr) * | 1986-04-22 | 1987-11-05 | L'oreal | Dispersion de spherules lipidiques |
| EP0424282A1 (fr) * | 1989-10-19 | 1991-04-24 | ERPHAR Société d'Etudes et de Recherches Pharmaceutiques et Cosmétiques | Préparation cosmétique de bronzage |
-
1991
- 1991-10-08 FR FR9112599A patent/FR2682039A1/fr active Granted
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2540381A1 (fr) * | 1983-02-08 | 1984-08-10 | Dior Sa Parfums Christian | Procede pour stimuler la croissance des cellules; composition cosmetique, pharmaceutique et composition complementaire pour milieu de culture cellulaire appliquant ce procede |
| EP0160286A2 (en) * | 1984-04-28 | 1985-11-06 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Liposomes |
| WO1987006460A1 (fr) * | 1986-04-22 | 1987-11-05 | L'oreal | Dispersion de spherules lipidiques |
| EP0424282A1 (fr) * | 1989-10-19 | 1991-04-24 | ERPHAR Société d'Etudes et de Recherches Pharmaceutiques et Cosmétiques | Préparation cosmétique de bronzage |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2852249A1 (fr) * | 2003-03-10 | 2004-09-17 | Christian Chavrier | Biomateriau de comblement osseux |
| JP2007182419A (ja) * | 2005-12-07 | 2007-07-19 | Tokyo Univ Of Science | プロリン誘導体及び光学活性アンチ選択性増強触媒 |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2682039B1 (enrdf_load_stackoverflow) | 1995-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2375413T3 (es) | Fragmentos peptídicos para inducir la síntesis de proteínas de la matriz extracelular. | |
| EP0972522B2 (fr) | Composition anti-inflammatoire | |
| EP0802784B1 (fr) | Milieu nutritif utilisable comme milieu de culture de cellules epidermiques et applications | |
| JP2022519715A (ja) | 皮膚、毛髪、爪および／または粘膜の処置および／またはケアに有用な化合物 | |
| EP0869969B1 (fr) | Conjugues peptidiques, leur utilisation a titre de medicament et compositions les contenant | |
| EP1406651B1 (fr) | Peptide et l'utilisation cosmetique ou dermatologique pour augmenter l'adhesion entre les cellules cutanees | |
| KR102103715B1 (ko) | 합성 PnTx(19) 펩타이드, 약학 조성물 및 용도 | |
| Ahuja et al. | Recent Advances in Smart Self‐Assembled Bioinspired Hydrogels: A Bridging Weapon for Emerging Health Care Applications from Bench to Bedside | |
| US10857199B2 (en) | Compounds and methods for increasing hair growth | |
| KR101721028B1 (ko) | 상처 치유 촉진용 조성물 | |
| FR2682039A1 (fr) | Compositions medicamenteuses destinees a favoriser le renouvellement a la matrice extracellulaire. | |
| Fridman et al. | Comparison of the effects of KE and AED peptides on functional activity of human skin fibroblasts during their replicative aging | |
| EP0537092A1 (fr) | Vecteurs vésiculaires infracellulaires et leurs applications dans les compositions cosmétiques, médicamenteuses et les milieux de culture | |
| US20070231400A1 (en) | Triggered release from proteinoid microspheres | |
| FR2682121A1 (fr) | Milieux synthetiques pour la culture des fibroblastes et leurs applications. | |
| FR2682038A1 (fr) | Vecteurs vesiculaires intracellulaires et leurs applications en cosmetique. | |
| US11236138B2 (en) | Peptide, method and composition for melanin polymerization and hair darkening | |
| EP1318829B1 (fr) | Tri- ou tétrapeptides angiogéniques dérivés de AcSDKP | |
| FR2637501A1 (fr) | Composition stabilisee a base de facteurs de croissance de la famille fgf et de dextrane sulfate, et ses applications | |
| US10232009B1 (en) | Peptide for promoting wound healing, its composition and method of using the same | |
| US20190380957A1 (en) | Protein Hydrogels For Treatment Of Neovascular Disease | |
| CN1917904B (zh) | 有机硅化合物用于约束受损结缔组织的用途 | |
| TWI859182B (zh) | 用於黑色素聚合及髮色變黑的胜肽、方法及組合物 | |
| EP1093359B1 (fr) | Procede de preparation de fibrilline a partir de cnidaires, et compositions obtenues utilisables en cosmetiques | |
| TW202506705A (zh) | 用於黑色素聚合及髮色變黑的胜肽、方法及組合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AM | Act modifying the rights related to an application or a patent | ||
| TP | Transmission of property | ||
| TQ | Partial transmission of property | ||
| ST | Notification of lapse |